{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:35:37Z","timestamp":1791362137170,"version":"4.3.1"},"reference-count":77,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary Sj\u00f6gren's syndrome (pSS) is an autoimmune systemic disease mainly affecting exocrine glands and resulting in disabling symptoms, as dry eye and dry mouth. Mechanisms underlying pSS pathogenesis are intricate, involving multiplanar and, at the same time, interlinked levels, e.g., genetic predisposition, epigenetic modifications and the dysregulation of both immune system and glandular-resident cellular pathways, mainly salivary gland epithelial cells. Unravelling the biological and molecular complexity of pSS is still a great challenge but much progress has been made in recent years in basic and translational research field, allowing the identification of potential novel targets for therapy development. Despite such promising novelties, however, none therapy has been specifically approved for pSS treatment until now. In recent years, growing evidence has supported the modulation of Janus kinases (JAK) - signal transducers and activators of transcription (STAT) pathways as treatment strategy immune mediated diseases. JAK-STAT pathway plays a crucial role in autoimmunity and systemic inflammation, being involved in signal pathways of many cytokines. This review aims to report the state-of-the-art about the role of JAK-STAT pathway in pSS, with particular focus on available research and clinical data regarding the use of JAK inhibitors in pSS.<\/jats:p>","DOI":"10.2478\/rir-2022-0017","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:51:20Z","timestamp":1666273880000},"page":"95-102","source":"Crossref","is-referenced-by-count":33,"title":["JAK\/STAT pathway targeting in primary Sj\u00f6gren syndrome"],"prefix":"10.2478","volume":"3","author":[{"given":"Saviana","family":"Gandolfo","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Internal Medicine , San Giovanni Bosco Hospital , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine , Universit\u00e0 della Campania Luigi Vanvitelli , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2023022814564793203_j_rir-2022-0017_ref_001","doi-asserted-by":"crossref","unstructured":"Moutsopoulos HM. Sjogren's Syndrome: Autoimmune Epithelitis. Clin Immunol Immunopathol. 1994;72:162\u2013165.","DOI":"10.1006\/clin.1994.1123"},{"key":"2023022814564793203_j_rir-2022-0017_ref_002","doi-asserted-by":"crossref","unstructured":"Mariette X, Criswell LA. Primary Sjogren's Syndrome. N Engl J Med. 2018;378:931\u2013939.","DOI":"10.1056\/NEJMcp1702514"},{"key":"2023022814564793203_j_rir-2022-0017_ref_003","doi-asserted-by":"crossref","unstructured":"Zintzaras E, Voulgarelis M, Moutsopoulos HM. The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-Analysis. Arch Intern Med. 2005;165:2337\u20132344.","DOI":"10.1001\/archinte.165.20.2337"},{"key":"2023022814564793203_j_rir-2022-0017_ref_004","doi-asserted-by":"crossref","unstructured":"Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant Lymphoma in Primary Sjogren's Syndrome: A Multicenter, Retrospective, Clinical Study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum. 1999;42:1765\u20131772.","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V"},{"key":"2023022814564793203_j_rir-2022-0017_ref_005","doi-asserted-by":"crossref","unstructured":"Chatzis L, Pezoulas VC, Ferro F, et al. Sjogren's Syndrome: The Clinical Spectrum of Male Patients. J Clin Med. 2020;9.","DOI":"10.3390\/jcm9082620"},{"key":"2023022814564793203_j_rir-2022-0017_ref_006","doi-asserted-by":"crossref","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology\/European League against Rheumatism Classification Criteria for Primary Sjogren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017;69:35\u201345.","DOI":"10.1002\/art.39859"},{"key":"2023022814564793203_j_rir-2022-0017_ref_007","doi-asserted-by":"crossref","unstructured":"Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The Role of Epithelial Cells in the Initiation and Perpetuation of Autoimmune Lesions: Lessons from Sjogren's Syndrome (Autoimmune Epithelitis). Lupus. 2006;15:255\u2013261.","DOI":"10.1191\/0961203306lu2290rr"},{"key":"2023022814564793203_j_rir-2022-0017_ref_008","doi-asserted-by":"crossref","unstructured":"Verstappen GM, Pringle S, Bootsma H, et al. Epithelial-Immune Cell Interplay in Primary Sjogren Syndrome Salivary Gland Pathogenesis. Nat Rev Rheumatol. 2021;17:333\u2013348.","DOI":"10.1038\/s41584-021-00605-2"},{"key":"2023022814564793203_j_rir-2022-0017_ref_009","doi-asserted-by":"crossref","unstructured":"Riviere E, Pascaud J, Tchitchek N, et al. Salivary Gland Epithelial Cells from Patients with Sjogren's Syndrome Induce B-Lymphocyte Survival and Activation. Ann Rheumatol Dis. 2020;79: 1468\u20131477.","DOI":"10.1136\/annrheumdis-2019-216588"},{"key":"2023022814564793203_j_rir-2022-0017_ref_010","doi-asserted-by":"crossref","unstructured":"Bjork A, Mofors J, Wahren-Herlenius M. Environmental Factors in the Pathogenesis of Primary Sjogren's Syndrome. J Intern Med. 2020;287:475\u2013492.","DOI":"10.1111\/joim.13032"},{"key":"2023022814564793203_j_rir-2022-0017_ref_011","doi-asserted-by":"crossref","unstructured":"Bowman SJ, Fox R, Dorner T, et al. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) in Patients with Primary Sjogren's Syndrome: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Dose-Finding Trial. Lancet. 2022;399:161\u2013171.","DOI":"10.1016\/S0140-6736(21)02251-0"},{"key":"2023022814564793203_j_rir-2022-0017_ref_012","doi-asserted-by":"crossref","unstructured":"Gandolfo S, De Vita S. Emerging Drugs for Primary Sjogren's Syndrome. Expert Opin Emerg Drugs. 2019;24:121\u2013132.","DOI":"10.1080\/14728214.2019.1634052"},{"key":"2023022814564793203_j_rir-2022-0017_ref_013","doi-asserted-by":"crossref","unstructured":"Wang F, Sun L, Wang S, et al. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clin Proc. 2020;95: 1404\u20131419.","DOI":"10.1016\/j.mayocp.2020.01.039"},{"key":"2023022814564793203_j_rir-2022-0017_ref_014","doi-asserted-by":"crossref","unstructured":"Keeling S, Maksymowych WP. JAK Inhibitors, Psoriatic Arthritis, and Axial Spondyloarthritis: A Critical Review of Clinical Trials. Expert Rev Clin Immunol. 2021;17:701\u2013715.","DOI":"10.1080\/1744666X.2021.1925541"},{"key":"2023022814564793203_j_rir-2022-0017_ref_015","doi-asserted-by":"crossref","unstructured":"Crispino N, Ciccia F. JAK\/STAT Pathway and Nociceptive Cytokine Signalling in Rheumatoid Arthritis and Psoriatic Arthritis. Clin Exp Rheumatol. 2021;39:668\u2013675.","DOI":"10.55563\/clinexprheumatol\/e7ayu8"},{"key":"2023022814564793203_j_rir-2022-0017_ref_016","doi-asserted-by":"crossref","unstructured":"You H, Xu D, Zhao J, et al. JAK Inhibitors: Prospects in Connective Tissue Diseases. Clin Rev Allergy Immunol. 2020;59: 334\u2013351.","DOI":"10.1007\/s12016-020-08786-6"},{"key":"2023022814564793203_j_rir-2022-0017_ref_017","doi-asserted-by":"crossref","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ. Mechanisms and Consequences of Jak-STAT Signaling in the Immune System. Nat Immunol. 2017;18:374\u2013384.","DOI":"10.1038\/ni.3691"},{"key":"2023022814564793203_j_rir-2022-0017_ref_018","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, et al. The JAK\/STAT Signaling Pathway: From Bench to Clinic. Signal Transduct Target Ther. 2021;6:402.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"2023022814564793203_j_rir-2022-0017_ref_019","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. N Engl J Med. 2012;367:508\u2013519.","DOI":"10.1056\/NEJMoa1112072"},{"key":"2023022814564793203_j_rir-2022-0017_ref_020","doi-asserted-by":"crossref","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. N Engl J Med. 2014;370: 2377\u20132386.","DOI":"10.1056\/NEJMoa1310476"},{"key":"2023022814564793203_j_rir-2022-0017_ref_021","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and Safety of Tofacitinib Monotherapy, Tofacitinib with Methotrexate, and Adalimumab with Methotrexate in Patients with Rheumatoid Arthritis (ORAL Strategy): A Phase 3b\/4, Double-Blind, Head-to-Head, Randomised Controlled Trial. Lancet. 2017;390:457\u2013468.","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2023022814564793203_j_rir-2022-0017_ref_022","doi-asserted-by":"crossref","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377:1537\u20131550.","DOI":"10.1056\/NEJMoa1615975"},{"key":"2023022814564793203_j_rir-2022-0017_ref_023","doi-asserted-by":"crossref","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376:652\u2013662.","DOI":"10.1056\/NEJMoa1608345"},{"key":"2023022814564793203_j_rir-2022-0017_ref_024","doi-asserted-by":"crossref","unstructured":"Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Phase III Randomised Clinical Trial. Ann Rheum Dis. 2021;80:848\u2013858.","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2023022814564793203_j_rir-2022-0017_ref_025","doi-asserted-by":"crossref","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019;322:315\u2013325.","DOI":"10.1001\/jama.2019.9055"},{"key":"2023022814564793203_j_rir-2022-0017_ref_026","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71:1788\u20131800.","DOI":"10.1002\/art.41032"},{"key":"2023022814564793203_j_rir-2022-0017_ref_027","doi-asserted-by":"crossref","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (SELECT-MONOTHERAPY): A Randomised, Placebo-Controlled, Double-Blind Phase 3 Study. Lancet. 2019;393:2303\u20132311.","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2023022814564793203_j_rir-2022-0017_ref_028","unstructured":"Grisius MM, Bermudez DK, Fox PC. Salivary and Serum Interleukin 6 in Primary Sjogren's Syndrome. J Rheumatol. 1997;24:1089\u20131091."},{"key":"2023022814564793203_j_rir-2022-0017_ref_029","doi-asserted-by":"crossref","unstructured":"Hulkkonen J, Pertovaara M, Antonen J, et al. Elevated Interleukin-6 Plasma Levels Are Regulated by the Promoter Region Polymorphism of the IL6 Gene in Primary Sjogren's Syndrome and Correlate with the Clinical Manifestations of the Disease. Rheumatology (Oxford). 2001;40:656\u2013661.","DOI":"10.1093\/rheumatology\/40.6.656"},{"key":"2023022814564793203_j_rir-2022-0017_ref_030","doi-asserted-by":"crossref","unstructured":"Zhao H, Li Q, Ye M, et al. Tear Luminex Analysis in Dry Eye Patients. Med Sci Monit. 2018;24:7595\u20137602.","DOI":"10.12659\/MSM.912010"},{"key":"2023022814564793203_j_rir-2022-0017_ref_031","doi-asserted-by":"crossref","unstructured":"Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 Receptor Inhibition in Primary Sjogren Syndrome: A Multicentre Double-Blind Randomised Placebo-Controlled Trial. Ann Rheum Dis 2021;80:329\u2013338.","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2023022814564793203_j_rir-2022-0017_ref_032","doi-asserted-by":"crossref","unstructured":"Kang KY, Kim HO, Kwok SK, et al. Impact of Interleukin-21 in the Pathogenesis of Primary Sjogren's Syndrome: Increased Serum Levels of Interleukin-21 and Its Expression in the Labial Salivary Glands. Arthritis Res Ther. 2011;13:R179.","DOI":"10.1186\/ar3504"},{"key":"2023022814564793203_j_rir-2022-0017_ref_033","doi-asserted-by":"crossref","unstructured":"Loureiro-Amigo J, Franco-Jarava C, Perurena-Prieto J, et al. Serum CXCL13, BAFF, IL-21 and IL-22 Levels Are Related to Disease Activity and Lymphocyte Profile in Primary Sjogren's Syndrome. Clin Exp Rheumatol. 2021;39 Suppl 133:131\u2013139.","DOI":"10.55563\/clinexprheumatol\/fp741f"},{"key":"2023022814564793203_j_rir-2022-0017_ref_034","doi-asserted-by":"crossref","unstructured":"Chen X, Jiang S, Zhou Z, et al. Increased Expression of Inter-leukin-21-Inducible Genes in Minor Salivary Glands Are Associated with Primary Sjogren's Syndrome Disease Characteristics. Rheumatology (Oxford). 2021;60:2979\u20132989.","DOI":"10.1093\/rheumatology\/keaa695"},{"key":"2023022814564793203_j_rir-2022-0017_ref_035","doi-asserted-by":"crossref","unstructured":"Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): A User Guide. RMD Open. 2015;1:e000022.","DOI":"10.1136\/rmdopen-2014-000022"},{"key":"2023022814564793203_j_rir-2022-0017_ref_036","doi-asserted-by":"crossref","unstructured":"Pontarini E, Murray-Brown WJ, Croia C, et al. Unique Expansion of IL-21+ Tfh and Tph Cells under Control of ICOS Identifies Sjogren's Syndrome with Etopic Germinal Centres and MALT Lymphoma. Ann Rheumatol Dis. 2020;79:1588\u20131599.","DOI":"10.1136\/annrheumdis-2020-217646"},{"key":"2023022814564793203_j_rir-2022-0017_ref_037","doi-asserted-by":"crossref","unstructured":"Ciccia F, Guggino G, Rizzo A, et al. Potential Involvement of IL-22 and IL-22-Producing Cells in the Inflamed Salivary Glands of Patients with Sjogren's Syndrome. Ann Rheumatol Dis. 2012;71: 295\u2013301.","DOI":"10.1136\/ard.2011.154013"},{"key":"2023022814564793203_j_rir-2022-0017_ref_038","doi-asserted-by":"crossref","unstructured":"Nguyen CQ, Hu MH, Li Y, et al. Salivary Gland Tissue Expression of Interleukin-23 and Interleukin-17 in Sjogren's Syndrome: Findings in Humans and Mice. Arthritis Rheumatol. 2008;58: 734\u2013743.","DOI":"10.1002\/art.23214"},{"key":"2023022814564793203_j_rir-2022-0017_ref_039","doi-asserted-by":"crossref","unstructured":"Barone F, Nayar S, Campos J, et al. IL-22 Regulates Lymphoid Chemokine Production and Assembly of Tertiary Lymphoid Organs. Proc Natl Acad Sci U S A. 2015;112:11024\u201311029.","DOI":"10.1073\/pnas.1503315112"},{"key":"2023022814564793203_j_rir-2022-0017_ref_040","doi-asserted-by":"crossref","unstructured":"Bikker A, van Woerkom JM, Kruize AA, et al. Increased Expression of Interleukin-7 in Labial Salivary Glands of Patients with Primary Sjogren's Syndrome Correlates with Increased Inflammation. Arthritis Rheumatol. 2010;62:969\u2013977.","DOI":"10.1002\/art.27318"},{"key":"2023022814564793203_j_rir-2022-0017_ref_041","doi-asserted-by":"crossref","unstructured":"Zhou J, Yu Q. Anti-IL-7 Receptor-Alpha Treatment Ameliorates Newly Established Sjogren's-Like Exocrinopathy in Non-obese Diabetic Mice. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2438\u20132447.","DOI":"10.1016\/j.bbadis.2018.04.010"},{"key":"2023022814564793203_j_rir-2022-0017_ref_042","doi-asserted-by":"crossref","unstructured":"Jin JO, Kawai T, Cha S, et al. Interleukin-7 Enhances the Th1 Response to Promote the Development of Sjogren's Syndrome-Like Autoimmune Exocrinopathy in Mice. Arthritis Rheumatol. 2013;65:2132\u20132142.","DOI":"10.1002\/art.38007"},{"key":"2023022814564793203_j_rir-2022-0017_ref_043","unstructured":"Gandolfo S, Bulfoni M, Fabro C, et al. Thymic Stromal Lymphopoietin Expression from Benign Lymphoproliferation to Malignant B-Cell Lymphoma in Primary Sjogren's Syndrome. Clin Exp Rheumatol. 2019;37 Suppl 118:55\u201364."},{"key":"2023022814564793203_j_rir-2022-0017_ref_044","unstructured":"Gandolfo S, Fabro C, Kapsogeorgou E, et al. Validation of Thymic Stromal Lymphopoietin as a Biomarker of Primary Sjogren's Syndrome and Related Lymphoproliferation: Results in Independent Cohorts. Clin Exp Rheumatol. 2020;38 Suppl 126: 189\u2013194."},{"key":"2023022814564793203_j_rir-2022-0017_ref_045","doi-asserted-by":"crossref","unstructured":"Riviere E, Pascaud J, Virone A, et al. Interleukin-7\/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjogren's Syndrome. Arthritis Rheumatol. 2021;73:631\u2013640.","DOI":"10.1002\/art.41558"},{"key":"2023022814564793203_j_rir-2022-0017_ref_046","doi-asserted-by":"crossref","unstructured":"Nezos A, Gravani F, Tassidou A, et al. Type I and II Interferon Signatures in Sjogren's Syndrome Pathogenesis: Contributions in Distinct Clinical Phenotypes and Sjogren's Related Lymphomagenesis. J Autoimmun. 2015;63:47\u201358.","DOI":"10.1016\/j.jaut.2015.07.002"},{"key":"2023022814564793203_j_rir-2022-0017_ref_047","doi-asserted-by":"crossref","unstructured":"Hall JC, Baer AN, Shah AA, et al. Molecular Subsetting of Interferon Pathways in Sjogren's Syndrome. Arthritis Rheumatol. 2015;67:2437\u20132446.","DOI":"10.1002\/art.39204"},{"key":"2023022814564793203_j_rir-2022-0017_ref_048","doi-asserted-by":"crossref","unstructured":"Soret P, Le Dantec C, Desvaux E, et al. A New Molecular Classification to Drive Precision Treatment Strategies in Primary Sjogren's Syndrome. Nat Commun. 2021;12:3523.","DOI":"10.1038\/s41467-021-23472-7"},{"key":"2023022814564793203_j_rir-2022-0017_ref_049","doi-asserted-by":"crossref","unstructured":"Apostolou E, Kapsogeorgou EK, Konsta OD, et al. Expression of Type III Interferons (IFNlambdas) and Their Receptor in Sjogren's Syndrome. Clin Exp Immunol. 2016;186:304\u2013312.","DOI":"10.1111\/cei.12865"},{"key":"2023022814564793203_j_rir-2022-0017_ref_050","unstructured":"Ha YJ, Choi YS, Kang EH, et al. Increased Expression of Interferon-Lambda in Minor Salivary Glands of Patients with Primary Sjogren's Syndrome and Its Synergic Effect with Interferon-Alpha on Salivary Gland Epithelial Cells. Clin Exp Rheumatol. 2018;36 Suppl 112:31\u201340."},{"key":"2023022814564793203_j_rir-2022-0017_ref_051","doi-asserted-by":"crossref","unstructured":"Negishi H, Taniguchi T, Yanai H. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. Cold Spring Harb Perspect Biol. 2018;10:a028423","DOI":"10.1101\/cshperspect.a028423"},{"key":"2023022814564793203_j_rir-2022-0017_ref_052","doi-asserted-by":"crossref","unstructured":"Nordmark G, Alm GV, Ronnblom L. Mechanisms of Disease: Primary Sjogren's Syndrome and the Type I Interferon System. Nat Clin Pract Rheumatol. 2006;2:262\u2013269.","DOI":"10.1038\/ncprheum0173"},{"key":"2023022814564793203_j_rir-2022-0017_ref_053","doi-asserted-by":"crossref","unstructured":"Lasfar A, Zloza A, Silk AW, et al. Interferon Lambda: Toward a Dual Role in Cancer. J Interferon Cytokine Res. 2019;39: 22\u201329.","DOI":"10.1089\/jir.2018.0046"},{"key":"2023022814564793203_j_rir-2022-0017_ref_054","doi-asserted-by":"crossref","unstructured":"Lazear HM, Schoggins JW. Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50:907\u2013923.","DOI":"10.1016\/j.immuni.2019.03.025"},{"key":"2023022814564793203_j_rir-2022-0017_ref_055","doi-asserted-by":"crossref","unstructured":"Nezos A, Makri P, Gandolfo S, et al. TREX1 Variants in Sjogren's Syndrome Related Lymphomagenesis. Cytokine. 2020;132: 154781.","DOI":"10.1016\/j.cyto.2019.154781"},{"key":"2023022814564793203_j_rir-2022-0017_ref_056","unstructured":"Quartuccio L, Mavragani CP, Nezos A, et al. Type I Interferon Signature May Influence the Effect of Belimumab on Immunoglobulin Levels, Including Rheumatoid Factor in Sjogren's Syndrome. Clin Exp Rheumatol. 2017;35:719\u2013720."},{"key":"2023022814564793203_j_rir-2022-0017_ref_057","doi-asserted-by":"crossref","unstructured":"Aota K, Yamanoi T, Kani K, et al. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-Gamma-Induced CXCL10 Production in Human Salivary Gland Ductal Cells. Inflammation. 2021;44:206\u2013216.","DOI":"10.1007\/s10753-020-01322-w"},{"key":"2023022814564793203_j_rir-2022-0017_ref_058","doi-asserted-by":"crossref","unstructured":"Wakamatsu E, Matsumoto I, Yasukochi T, et al. Overexpression of Phosphorylated STAT-1alpha in the Labial Salivary Glands of Patients with Sjogren's Syndrome. Arthritis Rheumatol. 2006;54:3476\u20133484.","DOI":"10.1002\/art.22176"},{"key":"2023022814564793203_j_rir-2022-0017_ref_059","doi-asserted-by":"crossref","unstructured":"Pertovaara M, Silvennoinen O, Isomaki P. Cytokine-Induced STAT1 Activation Is Increased in Patients with Primary Sjogren's Syndrome. Clin Immunol. 2016;165:60\u201367.","DOI":"10.1016\/j.clim.2016.03.010"},{"key":"2023022814564793203_j_rir-2022-0017_ref_060","doi-asserted-by":"crossref","unstructured":"Ciccia F, Guggino G, Rizzo A, et al. Interleukin (IL)-22 Receptor 1 Is Over-expressed in Primary Sjogren's Syndrome and Sjogren-Associated Non-Hodgkin Lymphomas and Is Regulated by IL-18. Clin Exp Immunol. 2015;181:219\u2013229.","DOI":"10.1111\/cei.12643"},{"key":"2023022814564793203_j_rir-2022-0017_ref_061","doi-asserted-by":"crossref","unstructured":"Vartoukian SR, Tilakaratne WM, Seoudi N, et al. Dysregulation of the Suppressor of Cytokine Signalling 3-Signal Transducer and Activator of Transcription-3 Pathway in the Aetiopathogenesis of Sjogren's Syndrome. Clin Exp Immunol. 2014;177:618\u2013629.","DOI":"10.1111\/cei.12377"},{"key":"2023022814564793203_j_rir-2022-0017_ref_062","doi-asserted-by":"crossref","unstructured":"Charras A, Arvaniti P, Le Dantec C, et al. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: A Promise for Patients with Sjogren's Syndrome. Clin Rev Allergy Immunol. 2020;58: 182\u2013193.","DOI":"10.1007\/s12016-019-08743-y"},{"key":"2023022814564793203_j_rir-2022-0017_ref_063","doi-asserted-by":"crossref","unstructured":"Groom JR, Luster AD. CXCR3 Ligands: Redundant, Collaborative and Antagonistic Functions. Immunol Cell Biol. 2011;89: 207\u2013215.","DOI":"10.1038\/icb.2010.158"},{"key":"2023022814564793203_j_rir-2022-0017_ref_064","doi-asserted-by":"crossref","unstructured":"Ogawa N, Ping L, Zhenjun L, et al. Involvement of the Interferon-Gamma-Induced T Cell-Attracting Chemokines, Interferon-Gamma-Inducible 10-kd Protein (CXCL10) and Monokine Induced by Interferon-Gamma (CXCL9), in the Salivary Gland Lesions of Patients with Sjogren's Syndrome. Arthritis Rheumatol. 2002;46: 2730\u20132741.","DOI":"10.1002\/art.10577"},{"key":"2023022814564793203_j_rir-2022-0017_ref_065","doi-asserted-by":"crossref","unstructured":"Aota K, Yamanoi T, Kani K, et al. Inverse Correlation between the Number of CXCR3(+) Macrophages and the Severity of Inflammatory Lesions in Sjogren's Syndrome Salivary Glands: A Pilot Study. J Oral Pathol Med. 2018;47:710\u2013718.","DOI":"10.1111\/jop.12756"},{"key":"2023022814564793203_j_rir-2022-0017_ref_066","doi-asserted-by":"crossref","unstructured":"Blokland SLM, Kislat A, Homey B, et al. Decreased Circulating CXCR3 + CCR9+T Helper Cells Are Associated with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Patients with Sjogren's Syndrome to Facilitate Their Concerted Migration. Scand J Immunol. 2020;91:e12852.","DOI":"10.1111\/sji.12852"},{"key":"2023022814564793203_j_rir-2022-0017_ref_067","doi-asserted-by":"crossref","unstructured":"Bai W, Liu H, Dou L, et al. Pilot Study of Baricitinib for Active Sjogren's Syndrome. 2022;81:1050\u20131052.","DOI":"10.1136\/annrheumdis-2021-222053"},{"key":"2023022814564793203_j_rir-2022-0017_ref_068","doi-asserted-by":"crossref","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. Lancet. 2018;392: 222\u2013231.","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2023022814564793203_j_rir-2022-0017_ref_069","doi-asserted-by":"crossref","unstructured":"Lee J, Lee J, Kwok SK, et al. JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjogren's Syndrome. Arthritis Rheumatol. 2018;70:2057\u20132066.","DOI":"10.1002\/art.40589"},{"key":"2023022814564793203_j_rir-2022-0017_ref_070","doi-asserted-by":"crossref","unstructured":"Price E, Bombardieri M, Kivitz A, et al. Safety and Efficacy of Filgotinib, Lanraplenib, and Tirabrutinib in Sjogren's Syndrome: Randomised, Phase 2, Double-Blind, Placebo-Controlled Study. 2022 Apr 4;keac167; Online ahead of print.","DOI":"10.1093\/rheumatology\/keac167"},{"key":"2023022814564793203_j_rir-2022-0017_ref_071","doi-asserted-by":"crossref","unstructured":"Seror R, Baron G, Camus M, et al. Development and Preliminary Validation of the Sjogren's Tool for Assessing Response (STAR): A Consensual Composite Score for Assessing Treatment Effect in Primary Sjogren's Syndrome. Ann Rheum Dis. 2022;81:979\u2013989.","DOI":"10.1136\/annrheumdis-2021-222054"},{"key":"2023022814564793203_j_rir-2022-0017_ref_072","doi-asserted-by":"crossref","unstructured":"Colafrancesco S, Barbati C, Priori R, et al. Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjogren's Syndrome. Arthritis Rheumatol. 2022;74:654\u2013664.","DOI":"10.1002\/art.42018"},{"key":"2023022814564793203_j_rir-2022-0017_ref_073","doi-asserted-by":"crossref","unstructured":"Colafrancesco S, Vomero M, Iannizzotto V, et al. Autophagy Occurs in Lymphocytes Infiltrating Sjogren's Syndrome Minor Salivary Glands and Correlates with Histological Severity of Salivary Gland Lesions. Arthritis Res Ther. 2020;22:238.","DOI":"10.1186\/s13075-020-02317-6"},{"key":"2023022814564793203_j_rir-2022-0017_ref_074","doi-asserted-by":"crossref","unstructured":"Harris J, Lang T, Thomas JPW, et al. Autophagy and Inflammasomes. Mol Immunol. 2017;86:10\u201315.","DOI":"10.1016\/j.molimm.2017.02.013"},{"key":"2023022814564793203_j_rir-2022-0017_ref_075","doi-asserted-by":"crossref","unstructured":"Barrera MJ, Aguilera S, Castro I, et al. Tofacitinib Counteracts IL-6 Overexpression Induced by Deficient Autophagy: Implications in Sjogren's Syndrome. Rheumatology (Oxford). 2021;60: 1951\u20131962.","DOI":"10.1093\/rheumatology\/keaa670"},{"key":"2023022814564793203_j_rir-2022-0017_ref_076","doi-asserted-by":"crossref","unstructured":"McCoy SS, Parker M, Gurevic I, et al. Ruxolitinib Inhibits IFN-gamma-Stimulated Sjogren's Salivary Gland MSC HLA-DR Expression and Chemokine-Dependent T-cell Migration. Rheumatology (Oxford) 2022;61:4207\u20134218","DOI":"10.1093\/rheumatology\/keac111"},{"key":"2023022814564793203_j_rir-2022-0017_ref_077","doi-asserted-by":"crossref","unstructured":"Pringle S, Wang X, Bootsma H, et al. Small-Molecule Inhibitors and the Salivary Gland Epithelium in Sjogren's Syndrome. Expert Opin Investig Drugs. 2019;28:605\u2013616.","DOI":"10.1080\/13543784.2019.1631796"}],"container-title":["Rheumatology and Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/rir-2022-0017\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/rir-2022-0017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T14:57:55Z","timestamp":1677596275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/rir-2022-0017\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2022,10,1]]}},"alternative-id":["10.2478\/rir-2022-0017"],"URL":"https:\/\/doi.org\/10.2478\/rir-2022-0017","relation":{},"ISSN":["2719-4523"],"issn-type":[{"value":"2719-4523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}